...
首页> 外文期刊>Transfusion: The Journal of the American Association of Blood Banks >Novel single-nucleotide change in GYP*A in a person who made an alloantibody to a new high-prevalence MNS antigen called ENEV.
【24h】

Novel single-nucleotide change in GYP*A in a person who made an alloantibody to a new high-prevalence MNS antigen called ENEV.

机译:对新型高流行性MNS抗原(称为ENEV)制造同素抗体的人中GYP * A的新型单核苷酸变化。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: Alloantibodies that define some high-prevalence MNS antigens are made by people with glycophorin A (GPA) altered by a single-amino-acid change or replacement of amino acids from part of the Pseudoexon 3 of GYP*B. The finding of a patient whose plasma contained a novel alloanti-En(a)FR prompted this study. RESULTS: The patient's serum contained an alloantibody to a high-prevalence antigen, resistant to papain, ficin, trypsin, alpha-chymotrypsin, or dithiothreitol. The antibody was strongly reactive with all panel red blood cells (RBCs) tested, showed reduced reactivity with ENEP- and ENAV- RBCs, and was nonreactive with M(k)M(k), En(a-), GP.Hil/GP.Hil, and GP.JL/M(k) RBCs. The patient's RBCs typed M+N-S+s-, Wr(a-b+(w)), ENEP-, and ENAV-. These results indicated that the antibody recognized a new high-prevalence antigen in the MNS system. Sequencing of DNA prepared from the patient's white blood cells revealed a GYP*A nucleotide substitution of 242T>G (predicted to change Val62 of GPA to Gly). This change ablates an RsaI restriction enzyme site and polymerase chain reaction-restriction fragment length polymorphism confirmed that the proband was homozygous for Nucleotide 242G. CONCLUSIONS: We describe a novel high-prevalence MNS antigen, characterized by Val62 in GPA and named ENEV. The absence of the antigen is associated with Gly62. The change explains the weakened reactivity of the patient's serum with ENEP- and ENAV- RBCs and nonreactivity with anti-ENEP and anti-ENAV against her RBCs. The ENEV antigen has been assigned the ISBT number MNS45.
机译:背景:定义某些高流行性MNS抗原的同种抗体是由糖蛋白A(GPA)的人生产的,该蛋白通过单氨基酸改变或GYP * B Pseudoexon 3部分的氨基酸置换而改变。发现患者血浆中含有新的alloanti-En(a)FR,促使这项研究。结果:患者的血清含有一种高流行抗原的同种抗体,对木瓜蛋白酶,丝蛋白,胰蛋白酶,α-胰凝乳蛋白酶或二硫苏糖醇有抗性。该抗体与所有测试的小组红细胞(RBC)都具有强反应性,与ENEP和ENAV- RBC的反应性降低,与M(k)M(k),En(a-),GP没有反应。 GP.Hil和GP.JL / M(k)RBC。患者的RBC类型为M + N-S + s-,Wr(a-b +(w)),ENEP-和ENAV-。这些结果表明该抗体在MNS系统中识别出一种新的高流行抗原。从患者白细胞制备的DNA测序显示GYP * A核苷酸取代为242T> G(预计会将GPA的Val62变为Gly)。该改变消除了RsaI限制性酶切位点,并且聚合酶链反应-限制性片段长度多态性证实了该先证者对于核苷酸242G是纯合的。结论:我们描述了一种新型的高流行性MNS抗原,其特征为GPA中的Val62,名为ENEV。抗原的缺乏与Gly62有关。这一变化说明了患者血清与ENEP和ENAV-RBC的反应性减弱,以及与抗ENP和抗ENAV对其RBC的反应性下降。 ENEV抗原已被指定为ISBT编号MNS45。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号